Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
480.77
+6.49 (1.37%)
Jun 12, 2026, 4:00 PM EDT - Market closed

Madrigal Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Madrigal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $678.71. The average 1-year stock price forecast is 41.17% higher than the current stock price, while the lowest is $542 (+12.74%) and the highest is $964 (+100.51%).

Price Target: $678.71 (+41.17%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$542$678.71$649.5$964
Change+12.74%+41.17%+35.10%+100.51%

Analyst Ratings

The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy121111111010
Buy333311
Hold222222
Sell000000
Strong Sell000000
Total171616161313

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Bank of America Securities
Bank of America Securities
Hold
Reiterates
$550$542
HoldReiterates$550$542+12.74%Jun 11, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$620
BuyReiterates$620+28.96%May 28, 2026
Truist Financial
Truist Financial
Buy
Reiterates
$709$514
BuyReiterates$709$514+6.83%May 26, 2026
Barclays
Barclays
Buy
Reiterates
$964
BuyReiterates$964+100.51%May 8, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$587$578
BuyMaintains$587$578+20.22%May 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.50B
from 958.40M
Increased by 56.04%
Revenue Next Year
2.21B
from 1.50B
Increased by 47.52%
EPS This Year
-6.52
from -12.73
EPS Next Year
12.38
from -6.52
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---180.13M958.40M1.50B
Revenue Growth
----432.05%56.04%
Gross Profit
---173.90M902.26M1.36B
Gross Margin
---96.54%94.14%91.04%
Operating Income
-242.48M-293.57M-380.50M-497.88M-300.10M-205.04M
Net Income
-241.85M-295.35M-373.63M-465.89M-288.28M-198.54M
EPS
-----12.73-6.52
Free Cash Flow
-94.62M-115.68M-192.38M-296.99M-115.08M-218.30M
No. Analysts
-----15
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.6B
Avg1.5B
Low1.4B

Revenue Growth

Revenue Growth202620272028
High
62.2%
Avg
56.0%
Low
46.2%

EPS Forecast

EPS202620272028
High-6.15
Avg-6.52
Low-7.11

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-